IRIS publication 284889191
The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat.
RIS format for Endnote and similar
TY - JOUR - Donovan MD, O'Brien FE, Boylan GB, Cryan JF, Griffin BT - 2015 - April - The Journal of pharmacy and pharmacology - The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat. - Published - Altmetric: 4 () - Recent data highlight the potential of bumetanide as a treatment for neonatal seizures and autism, as it facilitates the excitatory to inhibitory switch in gamma-aminobutyric acid signalling. This study examines the extent of blood-brain barrier (BBB) permeation of bumetanide, a key determinant of the efficacy of centrally acting drugs. Furthermore, the impact of efflux transporter organic anion transporter 3 (oat3) inhibition on bumetanide pharmacokinetics was investigated. - 10.1111/jphp.12341 DA - 2015/04 ER -
BIBTeX format for JabRef and similar
@article{V284889191, = {Donovan MD, O'Brien FE and Boylan GB, Cryan JF and Griffin BT }, = {2015}, = {April}, = {The Journal of pharmacy and pharmacology}, = {The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat.}, = {Published}, = {Altmetric: 4 ()}, = {{Recent data highlight the potential of bumetanide as a treatment for neonatal seizures and autism, as it facilitates the excitatory to inhibitory switch in gamma-aminobutyric acid signalling. This study examines the extent of blood-brain barrier (BBB) permeation of bumetanide, a key determinant of the efficacy of centrally acting drugs. Furthermore, the impact of efflux transporter organic anion transporter 3 (oat3) inhibition on bumetanide pharmacokinetics was investigated.}}, = {10.1111/jphp.12341}, source = {IRIS} }
Data as stored in IRIS
AUTHORS | Donovan MD, O'Brien FE, Boylan GB, Cryan JF, Griffin BT | ||
YEAR | 2015 | ||
MONTH | April | ||
JOURNAL_CODE | The Journal of pharmacy and pharmacology | ||
TITLE | The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat. | ||
STATUS | Published | ||
TIMES_CITED | Altmetric: 4 () | ||
SEARCH_KEYWORD | |||
VOLUME | |||
ISSUE | |||
START_PAGE | |||
END_PAGE | |||
ABSTRACT | Recent data highlight the potential of bumetanide as a treatment for neonatal seizures and autism, as it facilitates the excitatory to inhibitory switch in gamma-aminobutyric acid signalling. This study examines the extent of blood-brain barrier (BBB) permeation of bumetanide, a key determinant of the efficacy of centrally acting drugs. Furthermore, the impact of efflux transporter organic anion transporter 3 (oat3) inhibition on bumetanide pharmacokinetics was investigated. | ||
PUBLISHER_LOCATION | |||
ISBN_ISSN | |||
EDITION | |||
URL | |||
DOI_LINK | 10.1111/jphp.12341 | ||
FUNDING_BODY | |||
GRANT_DETAILS |